Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Among women with predominantly stage I HER2-positive breast cancer, treatment with adjuvant paclitaxel plus trastuzumab was associated with a risk of early recurrence of about 2%; 6% of patients withdrew from the study because of protocol-specified adverse events. (Funded by Genentech; ClinicalTrials.gov number, NCT00542451.).